Aspira Women’s Health Expands Co-Marketing and Distribution Collaboration with BioReference® to Include OvaWatch®
Aspira Women's Health has expanded its co-marketing and distribution collaboration with BioReference to include OvaWatch® in their portfolio. The partnership, which has included Ova1Plus® since 2022, will now market Aspira's complete OvaSuite portfolio to BioReference's healthcare provider clients. This expansion follows OvaWatch's approval by the New York State Department of Health's Clinical Laboratory Evaluation Program, making it available to over 15 million women in New York and New Jersey.
Aspira Women's Health ha ampliato la sua collaborazione di co-marketing e distribuzione con BioReference includendo OvaWatch® nel loro portafoglio. La partnership, che includeva Ova1Plus® dal 2022, ora commercializzerà l'intero portafoglio OvaSuite di Aspira ai clienti fornitori di servizi sanitari di BioReference. Questa espansione segue l'approvazione di OvaWatch da parte del Programma di Valutazione dei Laboratori Clinici del Dipartimento della Salute dello Stato di New York, rendendolo disponibile per oltre 15 milioni di donne a New York e nel New Jersey.
Aspira Women's Health ha ampliado su colaboración de co-marketing y distribución con BioReference para incluir OvaWatch® en su portafolio. La asociación, que incluía Ova1Plus® desde 2022, ahora comercializará el portafolio completo de OvaSuite de Aspira a los clientes proveedores de atención médica de BioReference. Esta expansión sigue la aprobación de OvaWatch por parte del Programa de Evaluación de Laboratorios Clínicos del Departamento de Salud del Estado de Nueva York, haciéndolo disponible para más de 15 millones de mujeres en Nueva York y Nueva Jersey.
Aspira Women's Health는 BioReference와의 공동 마케팅 및 유통 협력 관계를 확장하여 OvaWatch®를 그들의 포트폴리오에 포함시켰습니다. 2022년부터 Ova1Plus®를 포함해온 파트너십이 이제 Aspira의 전체 OvaSuite 포트폴리오를 BioReference의 의료 제공자 고객에게 마케팅할 것입니다. 이번 확장은 OvaWatch가 뉴욕주 보건부의 임상 실험실 평가 프로그램의 승인을 받은 후 이루어지며, 이를 통해 뉴욕과 뉴저지에서 1500만 명 이상의 여성에게 제공될 수 있습니다.
Aspira Women's Health a élargi sa collaboration de co-marketing et de distribution avec BioReference pour inclure OvaWatch® dans son portefeuille. Le partenariat, qui inclut Ova1Plus® depuis 2022, commercialisera désormais l'intégralité du portefeuille OvaSuite d'Aspira aux clients fournisseurs de soins de santé de BioReference. Cette expansion fait suite à l'approbation d'OvaWatch par le Programme d'Évaluation des Laboratoires Cliniques du Département de la Santé de l'État de New York, le rendant disponible pour plus de 15 millions de femmes à New York et dans le New Jersey.
Aspira Women's Health hat seine Co-Marketing- und Vertriebszusammenarbeit mit BioReference ausgeweitet, um OvaWatch® in ihr Portfolio aufzunehmen. Die Partnerschaft, die seit 2022 Ova1Plus® umfasst, wird nun Aspiras komplettes OvaSuite-Portfolio an die Kunden von BioReference im Gesundheitswesen vermarkten. Diese Erweiterung folgt auf die Genehmigung von OvaWatch durch das Klinische Laborbewertungsprogramm des Gesundheitsministeriums des Bundesstaates New York, wodurch es für über 15 Millionen Frauen in New York und New Jersey verfügbar wird.
- Expansion of market reach to 15+ million women in NY and NJ
- No additional costs incurred for OvaWatch adoption acceleration
- Strengthened partnership with established healthcare distributor BioReference
- None.
Insights
The expanded distribution agreement with BioReference marks a significant commercial milestone for Aspira Women's Health. The collaboration now covers the entire OvaSuite portfolio, including OvaWatch® and Ova1Plus®, targeting a substantial market of 15+ million women in New York and New Jersey. This strategic partnership leverages BioReference's established presence and distribution network without requiring additional infrastructure investment from Aspira.
The deal's value proposition is enhanced by the recent NYSDOH CLEP approval for OvaWatch, which removes regulatory barriers for market entry. BioReference's existing relationships with healthcare providers and proven success in co-marketing Ova1Plus since 2022 provides a strong foundation for accelerated market penetration. The partnership structure allows Aspira to expand its market reach while maintaining cost efficiency, which is important for a company with a market cap of
BioReference team is now able to provide the entire OvaSuite portfolio to healthcare providers in New York and New Jersey
AUSTIN, Texas, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (NASDAQ: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced the expansion of its co-marketing and distribution collaboration with BioReference Health, LLC (“BioReference”), a wholly-owned subsidiary of OPKO Health Inc. (NASDAQ: OPK), a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets.
Under the terms of the expanded agreement, Aspira and BioReference will join forces to market Aspira’s complete OvaSuite portfolio, including OvaWatch® and Ova1Plus®, to BioReference women’s healthcare provider clients. BioReference and Aspira have co-marketed and distributed Ova1Plus since 2022. The approval of OvaWatch by the New York State Department of Health’s (NYSDOH) Clinical Laboratory Evaluation Program (CLEP) in early October paved the way for the expanded relationship by making it available to the 15+ million women in New York and New Jersey.
Nicole Sandford, CEO of Aspira, expressed her enthusiasm for the expanded alliance, highlighting the shared goal of improving healthcare for women and the potential to accelerate OvaWatch adoption in New York and New Jersey without incurring additional costs.
Ellen Beausang, Chief Commercial Officer of BioReference, shared the excitement, emphasizing how the addition of OvaWatch to the Women's Health portfolio underscores BioReference Health's commitment to offering top-tier testing to aid women's health providers in New York and New Jersey in managing patients and helping improve patient outcomes.
About BioReference Health
BioReference® Health, LLC, empowers confident healthcare decisions by prioritizing service, creating innovative solutions, and offering scientific expertise in diagnostic testing. BioReference is headquartered in Elmwood Park, New Jersey, and is in-network with the largest health plans in the United States and processed more than 9 million tests in 2023. BioReference provides credible and tailored solutions for a variety of customers and patients, including medical practices small and large, hospitals and health systems, correctional institutions, and government agencies. In addition to an extensive test menu with 99 percent of tests performed in-house, BioReference’s differentiated offerings include large-scale health screening programs and transformative business solutions that optimize laboratory management. For more information, visit https://www.bioreference.com or on Facebook, Twitter, Instagram and LinkedIn.
About OvaWatch®
OvaWatch is the only non-invasive blood test available to assess the risk of ovarian cancer in patients with an adnexal mass initially evaluated as indeterminate or benign. With a
About Aspira Women’s Health Inc.
Aspira Women’s Health Inc. is dedicated to the discovery, development, and commercialization of noninvasive, AI-powered tests to aid in the diagnosis of gynecologic diseases.
OvaWatch® and Ova1Plus® are offered to clinicians as OvaSuiteSM. Together, they provide the only comprehensive portfolio of blood tests to aid in the detection of ovarian cancer risk for the 1.2+ million American women diagnosed with an adnexal mass each year. OvaWatch provides a negative predictive value of
Our in-development test pipeline will expand our ovarian cancer portfolio and address the tremendous need for non-invasive diagnostics for endometriosis, a debilitating disease that impacts millions of women worldwide. In ovarian cancer, we intend to combine microRNA and protein biomarkers with patient data to further enhance the sensitivity and specificity of our current tests. In endometriosis, we have developed the first-ever non-invasive test designed to identify endometriomas, one of the most commonly occurring forms of severe endometriosis. Through our ongoing endometriosis development program, we are combining microRNA and protein biomarkers with patient data, with the intent of identifying all endometriosis independent of disease location or severity.
Forward-Looking Statements
This press release contains forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve a number of risks and uncertainties. Such forward-looking statements include statements regarding, among other things, the timing and completion of any products in the pipeline development and other statements that are predictive in nature and whether the collaboration and marketing of the OvaSuite portfolio will prove successful. Actual results could differ materially from those discussed due to known and unknown risks, uncertainties, and other factors. These forward-looking statements generally can be identified by the use of words such as “designed to,” “expect,” “plan,” “anticipate,” “could,” “may,” “intend,” “will,” “continue,” “future,” other words of similar meaning and the use of future dates. These and additional risks and uncertainties are described more fully in the Company’s filings with the SEC, including those factors identified as “Risk Factors” in our most recent Annual Report on Form 10-K, for the fiscal year ended December 31, 2023, and subsequent Quarterly Reports on Form 10-Q. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Aspira presently does not know, or that Aspira currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Aspira’s expectations, plans, or forecasts of future events and views as of the date of this press release. Subsequent events and developments may cause the Company’s assessments to change. However, while Aspira may elect to update these forward-looking statements at some point in the future, Aspira expressly disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Aspira’s assessments of any date after the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.
Investor Relations Contact:
Jamie Sullivan
Director of Corporate Communications
Aspira Women’s Health
Investors@aspirawh.com
FAQ
What is the expanded collaboration between Aspira Women's Health (AWH) and BioReference in 2024?
When did OvaWatch (AWH) receive approval from New York State Department of Health?
How many women can access Aspira's (AWH) OvaWatch through the BioReference collaboration?
